Wilsey Asset Management Inc. Acquires 18,883 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Wilsey Asset Management Inc. grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.7% in the second quarter, HoldingsChannel reports. The fund owned 421,867 shares of the medical equipment provider’s stock after buying an additional 18,883 shares during the period. Zimmer Biomet makes up about 5.3% of Wilsey Asset Management Inc.’s portfolio, making the stock its 10th largest holding. Wilsey Asset Management Inc.’s holdings in Zimmer Biomet were worth $36,318,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its stake in shares of Zimmer Biomet by 9.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock worth $14,495,000 after acquiring an additional 13,883 shares during the period. Morningstar Investment Management LLC increased its stake in shares of Zimmer Biomet by 235.4% during the fourth quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock valued at $5,204,000 after acquiring an additional 40,610 shares during the period. Douglas Lane & Associates LLC raised its holdings in Zimmer Biomet by 6.7% during the fourth quarter. Douglas Lane & Associates LLC now owns 460,178 shares of the medical equipment provider’s stock worth $41,379,000 after purchasing an additional 28,818 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Zimmer Biomet by 257.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock worth $3,091,000 after purchasing an additional 24,748 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its position in Zimmer Biomet by 67.6% in the fourth quarter. CIBC Asset Management Inc now owns 46,516 shares of the medical equipment provider’s stock worth $4,183,000 after purchasing an additional 18,769 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Quarterly results exceeded expectations. Second-quarter sales rose 4.8% year over year to $2.177 billion, ahead of the $2.13 billion consensus estimate. Adjusted diluted EPS was $2.07, topping expectations of $2.01 and matching the prior-year period. Zimmer Biomet Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised or reaffirmed an upbeat full-year outlook. Zimmer Biomet provided 2026 adjusted EPS guidance of $8.47–$8.59 and revenue guidance of approximately $8.6 billion, with the revenue range above current consensus expectations. Reported diluted EPS increased 33.8% to $1.03. Zimmer Biomet raises guidance on Q2 beats
• Positive Sentiment: Analyst sentiment improved. Stifel Nicolaus raised its price target from $105 to $110 and maintained a Buy rating. TD Cowen also initiated or reiterated a Buy recommendation, providing additional support for the shares. Zimmer Biomet Holdings Gets a Buy from TD Cowen
• Neutral Sentiment: Growth initiatives are constructive but execution-dependent. Analysts highlighted strength in the U.S. hip business, new product launches and a channel-transformation effort as important drivers of the outlook. These initiatives could support future growth, although investors will monitor adoption and implementation.
• Negative Sentiment: Margins remain a concern. Despite the earnings beat, adjusted margins faced pressure, limiting the upside from stronger revenue. With the stock trading well above its 50- and 200-day moving averages and near the upper portion of its 52-week range, some investors may be taking profits or demanding clearer margin expansion before pushing the shares higher. ZBH’s Q2 Earnings Beat, 2026 View Raised

Zimmer Biomet Price Performance

NYSE ZBH opened at $97.13 on Friday. The stock has a market capitalization of $18.79 billion, a P/E ratio of 23.63, a P/E/G ratio of 2.88 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.69. The business’s fifty day moving average is $89.89 and its two-hundred day moving average is $90.09. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.5 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on ZBH. Leerink Partners initiated coverage on Zimmer Biomet in a research note on Monday, April 13th. They set a “hold” rating and a $101.00 price target for the company. BMO Capital Markets restated a “market perform” rating and issued a $96.00 price objective on shares of Zimmer Biomet in a report on Thursday. Zacks Research cut Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 27th. Citigroup lowered their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Finally, Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $104.00.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.